Skip to main content
Premium Trial:

Request an Annual Quote

Exiqon to Develop microRNA-Detection Products for Luminex's xMAP Platform

NEW YORK (GenomeWeb News) – Luminex and Exiqon said today that they have signed an agreement to co-develop and commercialize microRNA products for Luminex’s xMAP platform.
 
Under the terms of the agreement, Exiqon will develop and manufacture microRNA detection chemistries on behalf of the Luminex Bioscience Group.
 
The final microRNA products will be based on Luminex's xMAP instruments and Exiqon's Locked Nucleic Acid probes, nucleotide analogs that bind to RNA and DNA targets.
 
“By including LNAs in detection probes, it is possible to design very specific high-affinity detection assays for small RNA targets like miRNAs, which otherwise would not be possible using standard DNA-based detection probes,” the companies said in a statement.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.